Premium
Organ Chips: Quality Assurance Systems in Regenerative Medicine
Author(s) -
Pasqualini FS,
Emmert MY,
Parker KK,
Hoerstrup SP
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.527
Subject(s) - regenerative medicine , quality assurance , quality (philosophy) , product (mathematics) , computer science , key (lock) , organ system , risk analysis (engineering) , systems engineering , medicine , engineering , disease , stem cell , biology , pathology , microbiology and biotechnology , philosophy , external quality assessment , geometry , mathematics , epistemology , computer security
A class of novel therapies leverages regenerative cell types in disease microenvironments. This complex interplay challenges established good manufacturing practices, as standards and analytical tools to measure regenerative potency are missing. That is, we can build the product right, but we do not know if we are building the right product. Here, we suggest that organ‐chips, biomimetic in vitro phenotyping platforms, can serve as key quality assurance systems in regenerative medicine.